Vivek Subbiah, MD, on Dabrafenib/Trametinib Efficacy in Biliary Tract Cancer

According to a recent study, led by Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, dabrafenib in combination with trametinib is an effective treatment option for patients with BRAFV600E -mutated biliary tract cancer (BTC). In an interview with i3 Health, Dr. Subbiah shares insights on the significance of these study results and unmet needs and future treatment in this patient population. What are the most challenging aspects of treating patients with BRAFV600E -mutated ...
Continue reading

Dabrafenib/Trametinib Effective in Mutated Biliary Tract Cancer

Patients with biliary tract cancer often experience disease relapse after gemcitabine-based chemotherapy, representing an area of need in this patient population. In 5% of biliary tract tumors, a mutation in the BRAF gene is found. Dabrafenib in combination with trametinib has been shown to be an effective treatment option for patients with BRAFV600E – mutated cancers, particularly those with biliary tract cancer, according to a recent study, results of which were published in The Lancet Oncolog...
Continue reading

Metastatic Melanoma: Dabrafenib/Trametinib Improves Outcomes

Historically, patients with metastatic melanoma have a poor prognosis. However, due to the development of BRAF- and MEK-targeted therapies, patient outcomes have improved. To further characterize the outcomes associated with these treatments, researchers compiled and analyzed data from two clinical trials and found that in patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, dabrafenib plus trametinib had many long-term benefits in about one third of patients. D...
Continue reading

High-Risk Melanoma: Dabrafenib/Trametinib Preserves Quality of Life While Preventing Relapse

Previously, the researchers of the phase 3 COMBI-AD study found that adjuvant combination therapy consisting of dabrafenib (Taflinar®, Novartis) plus trametinib (Mekinist®, Novartis) helped to prevent relapse in patients with high-risk BRAF V600–mutant melanoma after surgical resection. The investigators now report that dabrafenib/trametinib combination therapy also helps to maintain quality of life. A targeted therapy drug, trametinib is an MEK inhibitor that works by targeting the MEK 1 and ME...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.